Ascendis Pharma A/S (NASDAQ:ASND) Price Target Increased to $191.00 by Analysts at Bank of America

Ascendis Pharma A/S (NASDAQ:ASND) had its price target boosted by Bank of America from $175.00 to $191.00 in a report issued on Monday, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other research analysts have also recently issued reports on the stock. Evercore ISI lifted their price objective on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an outperform rating in a research note on Tuesday, September 17th. Citigroup boosted their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a buy rating in a research note on Tuesday, September 17th. The Goldman Sachs Group boosted their target price on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a buy rating in a research note on Tuesday, September 17th. JPMorgan Chase & Co. decreased their target price on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an overweight rating on the stock in a research note on Wednesday, September 4th. Finally, StockNews.com raised shares of Ascendis Pharma A/S from a sell rating to a hold rating in a research note on Thursday, September 5th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus target price of $195.00.

Ascendis Pharma A/S Trading Down 3.1 %

NASDAQ ASND opened at $146.60 on Monday. The company has a 50 day moving average of $133.75 and a 200-day moving average of $136.50. The company has a market cap of $8.54 billion, a price-to-earnings ratio of -15.25 and a beta of 0.63. Ascendis Pharma A/S has a 1-year low of $85.29 and a 1-year high of $161.00.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently bought and sold shares of ASND. Gilbert & Cook Inc. lifted its holdings in Ascendis Pharma A/S by 8.4% in the fourth quarter. Gilbert & Cook Inc. now owns 2,838 shares of the biotechnology company’s stock valued at $357,000 after buying an additional 220 shares during the period. Quadrant Capital Group LLC raised its holdings in shares of Ascendis Pharma A/S by 90.4% during the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 151 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of Ascendis Pharma A/S by 1.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 16,384 shares of the biotechnology company’s stock valued at $2,064,000 after purchasing an additional 159 shares during the period. Trexquant Investment LP acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter valued at about $1,243,000. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Ascendis Pharma A/S by 37.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 91 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.